Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 4/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
INCR Stock Overview
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally.
InterCure Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₪20.27 |
52 Week High | ₪26.35 |
52 Week Low | ₪17.85 |
Beta | -0.47 |
1 Month Change | -10.55% |
3 Month Change | -8.24% |
1 Year Change | -12.37% |
3 Year Change | -37.37% |
5 Year Change | 869.32% |
Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
INCR | IL Pharmaceuticals | IL Market | |
---|---|---|---|
7D | 3.5% | 2.7% | 4.0% |
1Y | -12.4% | -36.4% | 7.1% |
Return vs Industry: INCR exceeded the IL Pharmaceuticals industry which returned -36.4% over the past year.
Return vs Market: INCR underperformed the IL Market which returned 7.1% over the past year.
Price Volatility
INCR volatility | |
---|---|
INCR Average Weekly Movement | 6.6% |
Pharmaceuticals Industry Average Movement | 7.8% |
Market Average Movement | 5.6% |
10% most volatile stocks in IL Market | 8.8% |
10% least volatile stocks in IL Market | 3.7% |
Stable Share Price: INCR is not significantly more volatile than the rest of IL stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: INCR's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | 350 | Alex Rabinovich | https://www.intercure.co |
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector.
InterCure Fundamentals Summary
INCR fundamental statistics | |
---|---|
Market Cap | ₪914.87m |
Earnings (TTM) | ₪14.85m |
Revenue (TTM) | ₪273.86m |
61.6x
P/E Ratio3.3x
P/S RatioIs INCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
INCR income statement (TTM) | |
---|---|
Revenue | ₪273.86m |
Cost of Revenue | ₪146.70m |
Gross Profit | ₪127.16m |
Other Expenses | ₪112.30m |
Earnings | ₪14.85m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | 0.33 |
Gross Margin | 46.43% |
Net Profit Margin | 5.42% |
Debt/Equity Ratio | 21.9% |
How did INCR perform over the long term?
See historical performance and comparisonValuation
Is INCR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for INCR?
Other financial metrics that can be useful for relative valuation.
What is INCR's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | ₪914.87m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 3.1x |
Enterprise Value/EBITDA | 16.7x |
PEG Ratio | 0.7x |
Price to Earnings Ratio vs Peers
How does INCR's PE Ratio compare to its peers?
INCR PE Ratio vs Peers |
---|
Company | PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 19x |
Price-To-Earnings vs Peers: INCR is expensive based on its Price-To-Earnings Ratio (61.6x) compared to the peer average (19x).
Price to Earnings Ratio vs Industry
How does INCR's PE Ratio compare vs other companies in the Pharmaceuticals Industry?
Price-To-Earnings vs Industry: INCR is expensive based on its Price-To-Earnings Ratio (61.6x) compared to the Asian Pharmaceuticals industry average (22x)
Price to Earnings Ratio vs Fair Ratio
What is INCR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 61.6x |
Fair PE Ratio | 86.3x |
Price-To-Earnings vs Fair Ratio: INCR is good value based on its Price-To-Earnings Ratio (61.6x) compared to the estimated Fair Price-To-Earnings Ratio (86.3x).
Share Price vs Fair Value
What is the Fair Price of INCR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: INCR (₪20.27) is trading above our estimate of fair value (₪0.68)
Significantly Below Fair Value: INCR is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: INCR is good value based on its PEG Ratio (0.7x)
Discover undervalued companies
Future Growth
How is InterCure forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score
5/6Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
90.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INCR's forecast earnings growth (90.7% per year) is above the savings rate (1.5%).
Earnings vs Market: INCR's earnings (90.7% per year) are forecast to grow faster than the IL market (3.9% per year).
High Growth Earnings: INCR's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: INCR's revenue (25.9% per year) is forecast to grow faster than the IL market (4% per year).
High Growth Revenue: INCR's revenue (25.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if INCR's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Past Performance
How has InterCure performed over the past 5 years?
Past Performance Score
4/6Past Performance Score 4/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-2.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INCR has high quality earnings.
Growing Profit Margin: INCR's current net profit margins (5.4%) are lower than last year (14.1%).
Past Earnings Growth Analysis
Earnings Trend: INCR has become profitable over the past 5 years, growing earnings by -2.9% per year.
Accelerating Growth: INCR's earnings growth over the past year (12.6%) exceeds its 5-year average (-2.9% per year).
Earnings vs Industry: INCR earnings growth over the past year (12.6%) exceeded the Pharmaceuticals industry 9%.
Return on Equity
High ROE: INCR's Return on Equity (3.7%) is considered low.
Discover strong past performing companies
Financial Health
How is InterCure's financial position?
Financial Health Score
4/6Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: INCR's short term assets (₪374.2M) exceed its short term liabilities (₪223.5M).
Long Term Liabilities: INCR's short term assets (₪374.2M) exceed its long term liabilities (₪35.7M).
Debt to Equity History and Analysis
Debt Level: INCR has more cash than its total debt.
Reducing Debt: INCR's debt to equity ratio has increased from 16.3% to 21.9% over the past 5 years.
Debt Coverage: INCR's debt is not well covered by operating cash flow (18.3%).
Interest Coverage: INCR's interest payments on its debt are well covered by EBIT (57.6x coverage).
Balance Sheet
Discover healthy companies
Dividend
What is InterCure current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate INCR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate INCR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INCR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INCR's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as INCR has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
2.3yrs
Average management tenure
CEO
Alex Rabinovich (50 yo)
3.42yrs
Tenure
₪180,000
Compensation
Mr. Alexander Rabinovich, also known as Alex, is Chief Executive Officer and Director of InterCure Ltd. since January 1, 2019 and July 9, 2018 respectively. Mr. Rabinovich is Chief Executive Officer and Di...
CEO Compensation Analysis
Compensation vs Market: Alex's total compensation ($USD52.13K) is below average for companies of similar size in the IL market ($USD551.97K).
Compensation vs Earnings: Alex's compensation has increased by more than 20% in the past year.
Leadership Team
Experienced Management: INCR's management team is considered experienced (2.3 years average tenure).
Board Members
Experienced Board: INCR's board of directors are considered experienced (3.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.6%.
Top Shareholders
Company Information
InterCure Ltd.'s employee growth, exchange listings and data sources
Key Information
- Name: InterCure Ltd.
- Ticker: INCR
- Exchange: TASE
- Founded: 1994
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₪914.865m
- Shares outstanding: 45.13m
- Website: https://www.intercure.co
Number of Employees
Location
- InterCure Ltd.
- 85 Medinat ha-Yehudim Street
- Herzliya
- 4676670
- Israel
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/06/24 00:00 |
End of Day Share Price | 2022/06/23 00:00 |
Earnings | 2022/03/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.